hrp0095p1-213 | Adrenals and HPA Axis | ESPE2022

Alterations in glucocorticoid metabolism as a possible cause of hypertension in childhood obesity

Martijn JJ Finken , JG Wirix Aleid , A von Rosenstiel-Jadoul Ines , van der Voorn Bibian , JM Chinapaw Mai , F Hartmann Michaela , E Kist-van Holthe Joana , A Wudy Stefan , Rotteveel Joost

Introduction: Childhood obesity is associated with alterations in hypothalamus-pituitary-adrenal axis activity. We tested the hypothesis that multiple alterations in the metabolism of glucocorticoids are required for the development of hypertension in children who become overweight.Methods: Timed spot urine for targeted gas chromatography-mass spectrometry steroid metabolome analysis was collected from (1) overweight/hyp...

hrp0095p1-444 | Diabetes and Insulin | ESPE2022

Influence of Family Status and Living Circumstances on Metabolic Control in Patients with Type 1 Diabetes

Schweizer Roland , Friz Silas , Hayn Clara , Lösch-Binder Martina , Uber Julia , Ziegler Julian , Liebrich Frankziska , Neu Andreas

Object and Aim: The quality of metabolism in type 1 diabetes depends on different external factors, e.g. the circumstances of living of a patient. We investigated how far the family status, living situation or own children have influence on metabolic control in patients who were transferred to adult care after long-term care in pediatric diabetology.Patients and Methods: From 1998 until 2019 we annually sent a questionna...

hrp0095p2-304 | Late Breaking | ESPE2022

Diabetic ketoacidosis associated with hypertriglyceridemia in the pediatric age group – A case report

Zorron Mariana , Duarte Gomes Machado Raquel , Albiero Camargo Daniela , Seben Julia , Fernanda Vanti Macedo Paulino Maria , Mendonça Erika , Fanger Vanessa

Introduction: Diabetic ketoacidosis (DKA) is a potentially fatal hyperglycemic emergency primarily associated with type 1 diabetes mellitus (T1D). The association between DKA and severe hypertriglyceridemia has already been previously discussed with a prevalence ranging between 7.1%-25%, with pancreatitis present in the majority of cases. Epidemiological data in the pediatric age are scarce and not well established. Its etiology is not yet fully known. The &qu...

hrp0092rfc2.2 | Bone, Growth Plate and Mineral Metabolism Session 1 | ESPE2019

Does the Treatment with Recombinant Human Growth Hormone Improve Final Height in Patients Affected by X-Linked Hypophosphatemia?

André Julia , Zhukouskaya Volha V. , Rothenbuhler Anya , Lambert Anne-Sophie , Salles Jean-Pierre , Mignot Brigitte , Linglart Agnès

Background/Aim: 25 to 40% of children with well-controlled X-linked hypophosphatemia (XLH) show linear growth failure, despite optimal conventional treatment (oral phosphate supplementation and active forms of vitamin D) with final height -2 SDS. Recombinant human growth hormone (rhGH) may be an adjuvant treatment of the growth retardation in these patients. Therefore, the main objective of this study was to describe how rhGH treatment improves final heigh...

hrp0092p1-59 | Fat, Metabolism and Obesity | ESPE2019

Growth Patterns in Non-syndromic Childhood Overweight: Comparing Children with Early of Late Onset Weight Gain

German Alina , Vaisbourd Julia , Wikland Kerstin Albertsson , Gelander Lars , Holmgren Anton , Niklasson Aimon , Hochberg Ze'ev

Background: A rapid weight gain during infancy increases adult lean body mass, whereas weight gain during adiposity rebound at age 4-7 years results in increased adult fat mass and an increased risk of the metabolic syndrome and T2D. To understand the impact of age of obesity onset on growth, we classified non-syndromic childhood overweight into an early onset (EO, age 0-3) and a late onset (LO, age 3-7) group and characterized the growth patterns of the two.<...

hrp0089fc6.5 | Fat, Metabolism and obesity | ESPE2018

The Role of Adipocytes in Childhood Precursor Bcell Lymphoblastic Leukemia

Brenner Elena Dorothea , Zinngrebe Julia , Dahlhaus Meike , Meyer Lueder-Hinrich , Wabitsch Martin , Debatin Klaus-Michael , Fischer-Posovszky Pamela

Acute lymphoblastic leukemia (ALL) is the most prevalent cancer in childhood. Over the past decades, survival rates increased, but relapse is still associated with a poor prognosis, especially if the bone marrow (BM) is affected. Marrow adipose tissue (MAT) constitutes a major part of the BM niche, but its impact on normal hematopoiesis versus leukemia initiation, progression and relapse has only recently gained attention. MAT is very sensitive to changes in the patientÂ’s...

hrp0086rfc8.7 | Growth: Clinical | ESPE2016

Safety and Tolerability of Once-Weekly Administration of CTP-Modified Human Growth Hormone (MOD-4023): 24-month Complete Dataset Results of a Phase 2 Study in Children with Growth Hormone Deficiency

Zelinska Nataliya , Skorodok Julia , Malievsky Oleg , Rosenfeld Ron G. , Zadik Zvi , Koren Ronit , Vander Shelly , Hart Gili , Radziuk Klaudziya

Background: Daily injections are currently required for growth hormone (GH) replacement therapy, which may cause poor compliance, inconvenience and distress for patients. MOD-4023 is a CTP-modified human GH (hGH) developed for once-weekly administration in growth hormone deficient (GHD) adults and children.Objective and hypotheses: In the present Phase 2 study, the safety and tolerability of once-weekly subcutaneous (SC) administration of MOD-4023 were a...

hrp0086rfc8.8 | Growth: Clinical | ESPE2016

Efficacy of Once-Weekly Administration of CTP-Modified Human Growth Hormone (MOD-4023): 24-month Complete Database Results of a Phase 2 Study in Children with Growth Hormone Deficiency

Zelinska Nataliya , Skorodok Julia , Malievsky Oleg , Rosenfeld Ron G. , Zadik Zvi , Koren Ronit , Vander Shelly , Hart Gili , Raduk Dmitri

Background: Growth hormone (GH) replacement therapy currently requires daily injections, which may cause poor compliance, inconvenience and distress for patients. CTP-modified hGH (MOD-4023) has been developed by OPKO Biologics for once-weekly administration in growth hormone-deficient (GHD) adults and children.Objective and hypotheses: The 24-month efficacy of once-weekly subcutaneous (SC) administration of MOD-4023 was evaluated in a Phase 2 study in G...

hrp0082p1-d3-83 | Diabetes (2) | ESPE2014

DKA During Diabetes Therapy: Multinational Comparison with 59 191 Pediatric Patients from England, Wales, The United States, Austria and Germany

Warner Justin , Hermann Julia , Kapellen Thomas , Hofer Sabine , Dubose Stephanie , Schatz Des , Beck Roy , Schweiger Claudia , Maahs David , Holl Reinhard

Background: DKA in children and adolescents with established type 1 diabetes (T1D) is a major problem with considerable cost to patients, families and health care systems. Many consider it as a quality of care indicator and a failure of relationship between the care provider and the family/patient. Considerable variability in rates are recognized. We analyzed multicenter registry and audit data from five countries with similarly advanced, yet differing, health care systems.</p...

hrp0082p1-d3-84 | Diabetes (2) | ESPE2014

Children and Adolescents with Type 1 Diabetes have Higher Plasma Visfatin Levels than Healthy Controls

Hontzsch Julia , Jasser-Nitsche Hildegard , Grillitsch Marlene , Suppan Elisabeth , Weinhandl Gudrun , Riedl Regina , Barowitsch Christine , Borkenstein Martin , Frohlich-Reiterer Elke

Background: The aim of this study was to examine plasma visfatin levels in pediatric patients with type 1 diabetes (T1D). Visfatin, a novel adipokine, is predominantly secreted by visceral adipose tissue and seems to have insulin-mimetic effects. It has not been studied in children and adolescents with type 1 diabetes (T1D) yet.Objectives: We studied 124 subjects; 62 patients with T1D: 31 girls, mean age 13.7±3.7 years; mean duration of diabetes 5.9...